---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059509"
form_type: "8-K"
ticker: null
cik: "0001394319"
company_name: "Tracon Pharmaceuticals, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:32:56.230247+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TRACON reports Q1 net loss $3.2M, cash $8.0M; ENVASARC final data due Q3 2024

## Summary
- Net loss for Q1 2024 was $3.2M, down from $8.5M in Q1 2023.
- Cash, cash equivalents and restricted cash were $8.0M at March 31, 2024, expected to fund operations late into Q3 2024.
- ENVASARC Phase 2 pivotal trial fully enrolled; final response assessment data expected in Q3 2024.
- Interim data: ORR 11% by investigator and 5.5% by BICR; median duration of response >6 months.
- Nasdaq listing extension granted through June 3, 2024, subject to reverse stock split and S-1 filing (both completed in April 2024).

## SEC filing metadata
- accession: 0000950170-24-059509
- form_type: 8-K
- cik: 0001394319
- company_name: Tracon Pharmaceuticals, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/0000950170-24-059509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/tcon-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059509
- JSON: https://secwatch.observer/filing/0000950170-24-059509.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059509.txt

## Key facts
- Earnings Releases
  Tracon Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $3.2 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss for the first quarter of 2024 was $3.2 million
  - Result: reported results
  source text: TRACON Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/0000950170-24-059509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.